drugset / Trial / NCT06132217
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.
Timeline
- Start
- 2024-01-30
- Primary completion
- 2027-01-30
- Completion
- 2027-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | — | Intravenous |
| Subject | Simmitinib | Small molecule | — | Oral |